CYTOBUOY B.V.

CYTOBUOY B.V. is a specialized contractor focused on advanced biomedical instrumentation and diagnostic system development, with core expertise rooted in flow cytometry, cell sorting technologies, and microfluidic platform design. The company delivers precision-engineered hardware and integrated software solutions for biological sample analysis, emphasizing high-throughput, multiparametric cell characterization and real-time data acquisition. Their technical capabilities include optical system design, laser-based detection architectures, embedded firmware development, and proprietary algorithmic analysis for cellular phenotyping. Differentiators include miniaturized instrument platforms optimized for field-deployable or lab-on-a-chip applications, with a strong emphasis on reproducibility, signal-to-noise optimization, and compliance with clinical diagnostic standards. No award history is available to infer specific agency engagements or contracting patterns. Consequently, there is insufficient data to identify primary federal clients or recurring mission areas served. The primary NAICS code 334516 corresponds to the manufacturing of medical, dental, and laboratory equipment, indicating CYTOBUOY B.V.’s market positioning within the life sciences instrumentation sector. The company operates at the intersection of biotechnology and precision engineering, serving research institutions, clinical diagnostics developers, and biopharmaceutical R&D environments that require customized analytical tools. Their focus is on high-performance, scalable instrumentation rather than consumables or software-only solutions. CYTOBUOY B.V. is structured as an X6 entity, indicating a small business classification under federal contracting rules, and is headquartered in Woerden, the Netherlands. While the company demonstrates technical specialization in biomedical instrumentation, no government certifications such as ISO 13485, FDA registration, or U.S. small business status are listed. Their geographic presence is limited to the Netherlands, with no public evidence of direct U.S. federal contracting activity or domestic operational footprint.